- Home
- ENTX vs EDF Comparison
ENTX vs EDF Comparison
Compare ENTX & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTX | EDF |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 151.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENTX | EDF |
|---|---|---|
| Price | $1.59 | $4.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 246.9K | 160.6K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $3.51 |
| 52 Week High | $3.22 | $5.50 |
Technical Indicators
Market Signals| Indicator | ENTX | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 44.67 |
| Support Level | $1.53 | $4.91 |
| Resistance Level | $1.78 | $5.04 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 15.69 | 34.75 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.